Dual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid Carcinoma: A Phase 2 Nonrandomized Clinical Trial

医学 无容量 易普利姆玛 内科学 甲状腺癌 肿瘤科 甲状腺癌 肾细胞癌 实体瘤疗效评价标准 癌 临床终点 甲状腺 癌症 胃肠病学 临床试验 临床研究阶段 免疫疗法
作者
Kartik Sehgal,Θεοδώρα Παππά,Kee‐Young Shin,Julia Schiantarelli,Mofei Liu,Cora A. Ricker,Naomi R. Besson,Stephanie M. Jones,Emma L. Welsh,Kathleen Lindahl Pfaff,Justine A. Barletta,Jihye Park,Brendan Michael Reardon,Gerard M. Doherty,Erik Karl Alexander,Scott J. Rodig,David Allen Barbie,Anne O’Neill,Eliezer M. Van Allen,Robert I. Haddad
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:10 (12): 1663-1663 被引量:58
标识
DOI:10.1001/jamaoncol.2024.4019
摘要

Importance: Aggressive thyroid carcinoma, including radioiodine refractory (RAIR) differentiated thyroid carcinoma (DTC), medullary thyroid carcinoma (MTC), and anaplastic thyroid carcinoma (ATC), are associated with significant morbidity and mortality and have limited therapeutic options. Distinct immune profiles have been identified in thyroid cancer subtypes suggesting they may be susceptible to immune checkpoint inhibition. Objective: To evaluate the efficacy of anti-programmed cell death 1 nivolumab and anti-cytotoxic lymphocyte-associated protein 4 ipilimumab in patients with aggressive thyroid carcinoma. Design, Setting, and Participants: This phase 2 nonrandomized clinical trial enrolled patients with RAIR DTC in a single center from October 2017 to May 2019, with exploratory cohorts in MTC and ATC. The data were analyzed between June 2021 and September 2023. Intervention: Intravenous nivolumab, 3 mg/kg, every 2 weeks and ipilimumab, 1 mg/kg, every 6 weeks until disease progression, intolerable adverse events, or a maximum duration of 2 years. Main Outcomes and Measures: The primary end point of the study was objective response rate (ORR) in RAIR DTC, which was scored according to RECIST (Response Evaluation Criteria in Solid Tumours), version 1.1. Key secondary end points included safety, progression-free survival, overall survival, and biomarker analyses. Results: A total of 51 patients were registered, and 49 patients were evaluable for analysis. The median (range) age was 65 years (30-88 years), and 25 participants (51%) were female. ORR in the DTC cohort was 9.4% (3/32 [95% CI, 2.8%-28.5%]), with all partial responses in either oncocytic carcinoma (2/6 [33.0%]) or poorly differentiated thyroid carcinoma (1/5 [20.0%]). Clinical benefit rates were 62.5% (20/32) in the overall DTC cohort, including 83.3% (5/6) in oncocytic carcinoma and 40% (2/5) in poorly differentiated thyroid carcinoma. ORR in the exploratory ATC cohort was 30.0% (3/10 [95% CI, 6.7%-65.2%]), with a clinical benefit rates of 50.0% (5/10). No responses were observed in the exploratory MTC cohort. The safety profile was similar to prior reports with dual immune checkpoint inhibition (pruritus, rash, diarrhea, fatigue, and elevation of lipase and liver enzymes). The presence of NRAS tumor genetic sequence variations, but not BRAF V600E, was associated with worse outcomes. Conclusions and Relevance: This phase 2 nonrandomized clinical trial reported clinical activity of dual immune checkpoint inhibition in aggressive thyroid cancer. The study did not meet its end point in the primary population of RAIR DTC and does not support further investigation in non-biomarker-selected DTC. However, the signal observed in ATC may merit further evaluation. Trial Registration: ClinicalTrials.gov Identifier: NCT03246958.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
一羽毛完成签到,获得积分10
1秒前
fff发布了新的文献求助10
1秒前
1秒前
Estelle_Chan发布了新的文献求助10
2秒前
2秒前
yi关闭了yi的文献求助
3秒前
周周周发布了新的文献求助10
4秒前
累土星辰完成签到,获得积分20
4秒前
852的应助被CCCCCL采纳,获得10
4秒前
黑米粥发布了新的文献求助200
5秒前
6秒前
6秒前
思源的应助被明亮的映天采纳,获得10
7秒前
jenny完成签到,获得积分10
7秒前
Changfh发布了新的文献求助10
8秒前
8秒前
所所的应助被xiaoxuey采纳,获得10
8秒前
常被暗恋完成签到 ,获得积分10
9秒前
Marciu33发布了新的文献求助10
9秒前
9秒前
英俊的铭的应助被zzz采纳,获得10
10秒前
11秒前
12秒前
orixero的应助被viviyoung采纳,获得10
12秒前
xiongjie发布了新的文献求助10
12秒前
12秒前
Sepnine9发布了新的文献求助20
12秒前
妞妞完成签到 ,获得积分10
13秒前
南州发布了新的文献求助10
13秒前
369ninja发布了新的文献求助10
14秒前
leotao发布了新的文献求助10
14秒前
樊冀鑫发布了新的文献求助10
15秒前
16秒前
17秒前
leotao发布了新的文献求助20
17秒前
17秒前
17秒前
17秒前
18秒前
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184336
求助须知:如何正确求助?哪些是违规求助? 9573358
关于积分的说明 21830993
捐赠科研通 7781367
什么是DOI,文献DOI怎么找? 3434307
关于科研通互助平台的介绍 2558401
邀请新用户注册赠送积分活动 2480846